Serum S100B in Pregnancy-Related Hypertensive Disorders: A Case–Control Study

Abstract

precision has been stated to be 11.6 mol/L (10 ). The imprecision (CV) for total bilirubin measurements on the Olympus analyzer ranged from 4.2% at a concentration of 123.1 mol/L to 2.8% at a concentration of 372.8 mol/L.The ability to measure bilirubin concentrations in newborns simply, rapidly, accurately, cost-effectively, and with minimal risk or discomfort has taken on increased importance in the current environment of managed care, capitation, litigation, and brief postpartum hospitalization. Measurement of bilirubin by various transcutaneous techniques has been reported from several studies with mixed results (5,(7)(8)(9)(10)(15)(16)(17)(18)(19). Race, as assessed by skin color score, did not have an effect on the performance of the BiliCheck method. In addition, other potential confounding factors, such as birth weight, gestational age, and postnatal age, did not affect the BiliCheck device.The results of our study may have been influenced by several factors. Freezing and storage of samples for HPLC analysis might have led to some degradation of bilirubin. However, the data shown in the Bland-Altman difference plots suggest that bilirubin degradation was not a significant factor. Other factors that might have influenced our results were the demographics of newborns evaluated in our study. All infants were Ͼ32 weeks of gestational age, none had undergone phototherapy, and all were Ͻ4 days of age. In addition, all transcutaneous measurements were performed in duplicate by a single individual, whereas singleton determinations by multiple caregivers would most likely be performed in routine practice.Currently, measurement of total bilirubin in serum or plasma of newborns is the standard of care for the assessment of neonatal jaundice. Our results indicate that the transcutaneous measurement of bilirubin is as accurate as bilirubin measured in plasma in a hospital laboratory when HPLC is used as the comparison method. In conclusion, measurement of bilirubin by the BiliCheck device offers an accurate, rapid, and noninvasive means of assessing plasma bilirubin concentrations in neonates.We thank Respironics (Marietta, GA) for supplying the reagents used in this study. We also acknowledge the cooperation of the newborn nursing staff at Pitt County Memorial Hospital.

High Maternal Blood S100B Concentrations in Pregnancies Complicated by Intrauterine Growth Restriction and Intraventricular Hemorrhage

“…In any case, one should assume that large increases in S100B concentrations in fetal and/or placental tissues would lead to an appreciable increase in the maternal blood in spite of the dilution effect attributable to the higher volume of the maternal bloodstream. Obviously, S100B can also derive from maternal tissues, as reported recently (36 ). Because all pregnant women enrolled in the present study were in healthy condition and had no detectable overt neurologic syndromes, the possibility that the protein originates from damaged maternal nervous system cells seems fairly remote.…”

A leading role for the immune system in the pathophysiology of preeclampsia

“…In hypoxic microenvironments, DAMPs may not be oxidized and denatured and thus, may promote inflammation [50] through ligation of receptors, such as RAGE, TLR2, and TLR4, which are expressed in immune system cells [51]. S100 and HMGB1 are proteins that behave as DAMPs [51,52]. High cytoplasmic expression of HMGB1 occurs in decidual cells of preeclamptic patients [53], and S100B is increased in amniotic fluid during preeclamptic pregnancies [54] in direct relation to oxidative stress [55].…”

S100B Mediates Stemness of Ovarian Cancer Stem-Like Cells Through Inhibiting p53

“…S100B is one of the members of the S100 protein family containing 21 types of EF‐hand Ca 2+ binding proteins. Aberrant S100B expression has been reported in different pathologies, including neurodegenerative disorders and cancers . It is reported that circulating S100B concentrations are the biomarker of malignant melanoma .…”